Transcription factor EHF drives cholangiocarcinoma development through transcriptional activation of glioma-associated oncogene homolog 1 and chemokine CCL2

Abstract

Cholangiocarcinoma (CCA) is characterized by rapid onset and high chance of metastasis. Therefore, identification of novel therapeutic targets is imperative. E26 transformation-specific homologous factor (EHF), a member of the E26 transformation-specific transcription factor family, plays a pivotal role in epithelial cell differentiation and cancer progression. However, its precise role in CCA remains unclear. In this study, through in vitro and in vivo experiments, we demonstrated that EHF plays a profound role in promoting CCA by transcriptional activation of glioma-associated oncogene homolog 1 (GLI1). Moreover, EHF significantly recruited and activated tumor-associated macrophages (TAMs) through the C-C motif chemokine 2/C-C chemokine receptor type 2 (CCL2/CCR2) axis, thereby remodeling the tumor microenvironment. In human CCA tissues, EHF expression was positively correlated with GLI1 and CCL2 expression, and patients with co-expression of EHF/GLI1 or EHF/CCL2 had the most adverse prognosis. Furthermore, the combination of the GLI1 inhibitor, GANT58, and CCR2 inhibitor, INCB3344, substantially reduced the occurrence of EHF-mediated CCA. In summary, our findings suggest that EHF is a potential prognostic biomarker for patients with CCA, while also advocating the therapeutic approach of combined targeting of GLI1 and CCL2/CCR2-TAMs to inhibit EHF-driven CCA development.

Keywords

cholangiocarcinogenesis / combined treatment / E26 transformation-specific homologous factor / tumor-associated macrophages

References

1	J Bridgewater, PR Galle, SA Khan, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60(6):1268-1289.
2	S Rizvi, SA Khan, CL Hallemeier, RK Kelley, GJ Gores. Cholangiocarcinoma—evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15(2):95-111.
3	H Sung, J Ferlay, RL Siegel, et al. Global cancer statistics 2020: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.
4	SA Khan, S Tavolari, G Brandi. Cholangiocarcinoma: epidemiology and risk factors. Liver Int. 2019;39(1):19-31.
5	RK Kelley, J Bridgewater, GJ Gores, AX Zhu. Systemic therapies for intrahepatic cholangiocarcinoma. J Hepatol. 2020;72(2):353-363.
6	BJ Graves, JM Petersen. Specificity within the ETS family of transcription factors. Adv Cancer Res. 1998;75: 1-55.
7	GM Sizemore, JR Pitarresi, S Balakrishnan, MC Ostrowski. The ETS family of oncogenic transcription factors in solid tumours. Nat Rev Cancer. 2017;17(6):337-351.
8	MA Bochert, LA Kleinbaum, LY Sun, FH Burton. Molecular cloning and expression of EHF, a new member of the ETS transcription factor/oncoprotein gene family. Biochem Biophys Res Commun. 1998;246(1):176-181.
9	T Oikawa, T Yamada. Molecular biology of the ETS family of transcription factors. Gene. 2003;303: 11-34.
10	J Wang, X Leng, G Wang, X Wan, H Cao. The construction of intrahepatic cholangiocarcinoma model in zebrafish. Sci Rep. 2017;7(1):13419.
11	KW Kinzler, JM Ruppert, SH Bigner, B Vogelstein. The GLI gene is a member of the Kruppel family of zinc finger proteins. Nature. 1988;332(6162):371-374.
12	A Ruiz i Altaba. Gli proteins encode context-dependent positive and negative functions: implications for development and disease. Development. 1999;126(14):3205-3216.
13	A Ruiz i Altaba, C Mas, B Stecca. The Gli code: an information nexus regulating cell fate, stemness and cancer. Trends Cell Biol. 2007;17(9):438-447.
14	D Doheny, SG Manore, GL Wong, HW Lo. Hedgehog signaling and truncated GLI1 in cancer. Cells. 2020;9(9):2114.
15	V Koh, J Chakrabarti, M Torvund, et al. Hedgehog transcriptional effector GLI mediates mTOR-induced PD-L1 expression in gastric cancer organoids. Cancer Lett. 2021;518: 59-71.
16	H Zhu, RL Carpenter, W Han, HW Lo. The GLI1 splice variant TGLI1 promotes glioblastoma angiogenesis and growth. Cancer Lett. 2014;343(1):51-61.
17	D Yuan, S Huang, E Berger, et al. Kupffer cell-derived TNF triggers cholangiocellular tumorigenesis through JNK due to chronic mitochondrial dysfunction and ROS. Cancer Cell. 2017;31(6):771-789. e776.
18	PP Hou, LJ Luo, HZ Chen, et al. Ectosomal PKM2 promotes HCC by inducing macrophage differentiation and remodeling the tumor microenvironment. Mol Cell. 2020;78(6):1192-1206. e1110.
19	K Cheng, N Cai, J Zhu, X Yang, H Liang, W Zhang. Tumor-associated macrophages in liver cancer: from mechanisms to therapy. Cancer Commun (Lond). 2022;42(11):1112-1140.
20	BJ Dwyer, EJ Jarman, J Gogoi-Tiwari, et al. TWEAK/Fn14 signalling promotes cholangiocarcinoma niche formation and progression. J Hepatol. 2021;74(4):860-872.
21	A Mantovani, P Allavena, A Sica, F Balkwill. Cancer-related inflammation. Nature. 2008;454(7203):436-444.
22	S Hao, J Meng, Y Zhang, et al. Macrophage phenotypic mechanomodulation of enhancing bone regeneration by superparamagnetic scaffold upon magnetization. Biomaterials. 2017;140: 16-25.
23	M Egawa, K Mukai, S Yoshikawa, et al. Inflammatory monocytes recruited to allergic skin acquire an anti-inflammatory M2 phenotype via basophil-derived interleukin-4. Immunity. 2013;38(3):570-580.
24	H Yang, M Yan, W Li, L Xu. SIRPα and PD1 expression on tumor-associated macrophage predict prognosis of intrahepatic cholangiocarcinoma. J Transl Med. 2022;20(1):140.
25	Y Wei, Q Zhao, Z Gao, et al. The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy. J Clin Invest. 2019;129(8):3347-3360.
26	S Zhang, X Song, D Cao, Z Xu, et al. Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice. J Hepatol. 2017;67(6):1194-1203.
27	L Tang, YX Tan, BG Jiang, et al. The prognostic significance and therapeutic potential of hedgehog signaling in intrahepatic cholangiocellular carcinoma. Clin Cancer Res. 2013;19(8):2014-2024.
28	L Fabris, K Sato, G Alpini, M Strazzabosco. The tumor microenvironment in cholangiocarcinoma progression. Hepatology. 2021;73(1):75-85.
29	E Loeuillard, J Yang, E Buckarma, et al. Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma. J Clin Invest. 2020;130(10):5380-5396.
30	M Xie, Z Lin, X Ji, et al. FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2. J Hepatol. 2023;79(1):109-125.
31	H Yang, Q Zhang, M Xu, et al. CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis. Mol Cancer. 2020;19(1):41.
32	BZ Qian, J Li, H Zhang, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011;475(7355):222-225.
33	J Dittmer, A Nordheim. ETS transcription factors and human disease. Biochim Biophys Acta. 1998;1377(2):F1-F11.
34	IY Luk, CM Reehorst, JM Mariadason. ELF3, ELF5, EHF and SPDEF transcription factors in tissue homeostasis and cancer. Molecules. 2018;23(9):2191.
35	AD Sharrocks. The ETS-domain transcription factor family. Nat Rev Mol Cell Biol. 2001;2(11):827-837.
36	D Albino, N Longoni, L Curti, et al. ESE3/EHF controls epithelial cell differentiation and its loss leads to prostate tumors with mesenchymal and stem-like features. Cancer Res. 2012;72(11):2889-2900.
37	T Zhou, J Liu, Y Xie, et al. ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4. Gut. 2022;71(2):357-371.
38	Z Cheng, J Guo, L Chen, N Luo, W Yang, X Qu. Knockdown of EHF inhibited the proliferation, invasion and tumorigenesis of ovarian cancer cells. Mol Carcinog. 2016;55(6):1048-1059.
39	K Brenne, DA Nymoen, TE Hetland, CG Trope, B Davidson. Expression of the ETS transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival. Hum Pathol. 2012;43(4):496-505.
40	K Taniue, T Oda, T Hayashi, M Okuno, T Akiyama. A member of the ETS family, EHF, and the ATPase RUVBL1 inhibit p53-mediated apoptosis. EMBO Rep. 2011;12(7):682-689.
41	J Taipale, MK Cooper, T Maiti, PA Beachy. Patched acts catalytically to suppress the activity of smoothened. Nature. 2002;418(6900):892-897.
42	AN Sigafoos, BD Paradise, ME Fernandez-Zapico. Hedgehog/GLI signaling pathway: transduction, regulation, and implications for disease. Cancers (Basel). 2021;13(14):3410.
43	J Ding, HY Li, L Zhang, Y Zhou, J Wu. Hedgehog signaling, a critical pathway governing the development and progression of hepatocellular carcinoma. Cells. 2021;10(1):123.
44	K Cho, H Moon, SH Seo, SW Ro, BK Kim. Pharmacological inhibition of sonic hedgehog signaling suppresses tumor development in a murine model of intrahepatic cholangiocarcinoma. Int J Mol Sci. 2021;22(24):13214.
45	C Chen, W He, J Huang, et al. LNMAT1 promotes lymphatic metastasis of bladder cancer via CCL2 dependent macrophage recruitment. Nat Commun. 2018;9(1):3826.
46	W Huang, Z Chen, L Zhang, et al. Interleukin-8 induces expression of FOXC1 to promote transactivation of CXCR1 and CCL2 in hepatocellular carcinoma cell lines and formation of metastases in mice. Gastroenterology. 2015;149(4):1053-1067. e1014.
47	F Tacke. Targeting hepatic macrophages to treat liver diseases. J Hepatol. 2017;66(6):1300-1312.